Sol-Gel completes patient follow-up in Gorlin syndrome Phase 3 trial
The last enrolled patient finished the final study visit for SGT-610 in Gorlin syndrome, with top-line data still expected late November 2026.
SEC filing
Latest
3 stories
Thursday, September 17
Thursday, August 20
Sol-Gel reports Q2 2026 results, SGT-610 Phase 3 readout on track for late November
Trial dropout rate is running lower than expected as Sol-Gel advances new studies in high-frequency BCC and Mohs surgery neo-adjuvant use.
SEC filing